Stable atypical chest pain with negative anatomical or functional diagnostic test: Diagnosis no matter what or prevention at any cost?


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 06 06 2019
revised: 13 08 2019
accepted: 14 08 2019
pubmed: 23 8 2019
medline: 18 2 2020
entrez: 22 8 2019
Statut: ppublish

Résumé

Approximately 1% to 2% of patients with stable atypical chest pain (SACP) experienced a major coronary event, even after a negative functional or anatomical test. Over the past 15 years, 1706 patients with SACP evaluated in our clinics underwent functional stress testing or coronary computed tomographic angiography (CTA). In these patients, we also assessed the presence of three major modifiable lifestyle-related risk factors (cigarette smoking, low intake of fruit and vegetables, and physical inactivity). Patients were stratified according to the presence of at least one risky lifestyle factor or no risky lifestyle factors. Functional or anatomical tests were positive in 170 patients (10%). We followed the remaining 1536 patients with negative tests for 1 year to evaluate the incidence of major coronary events. The percentage of patients reporting major coronary events was 1.2% in the group with risky lifestyles and 0.2% in the non-risky lifestyle group (P < .01). Events were more common in smokers. Patients with SACP, when functional or anatomical tests are negative, have a residual risk of fatal and non-fatal cardiovascular events of 1% at 1 year of follow-up. People with incorrect lifestyles, especially smokers, have a higher risk of events. We think that in this population, a more effective intervention on lifestyles could be the key to reduce major cardiovascular events.

Sections du résumé

BACKGROUND BACKGROUND
Approximately 1% to 2% of patients with stable atypical chest pain (SACP) experienced a major coronary event, even after a negative functional or anatomical test.
METHODS METHODS
Over the past 15 years, 1706 patients with SACP evaluated in our clinics underwent functional stress testing or coronary computed tomographic angiography (CTA). In these patients, we also assessed the presence of three major modifiable lifestyle-related risk factors (cigarette smoking, low intake of fruit and vegetables, and physical inactivity). Patients were stratified according to the presence of at least one risky lifestyle factor or no risky lifestyle factors. Functional or anatomical tests were positive in 170 patients (10%). We followed the remaining 1536 patients with negative tests for 1 year to evaluate the incidence of major coronary events.
RESULTS RESULTS
The percentage of patients reporting major coronary events was 1.2% in the group with risky lifestyles and 0.2% in the non-risky lifestyle group (P < .01). Events were more common in smokers.
CONCLUSIONS CONCLUSIONS
Patients with SACP, when functional or anatomical tests are negative, have a residual risk of fatal and non-fatal cardiovascular events of 1% at 1 year of follow-up. People with incorrect lifestyles, especially smokers, have a higher risk of events. We think that in this population, a more effective intervention on lifestyles could be the key to reduce major cardiovascular events.

Identifiants

pubmed: 31432542
doi: 10.1002/clc.23250
pmc: PMC6788466
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

982-987

Informations de copyright

© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.

Références

J Am Coll Cardiol. 2017 May 2;69(17):2149-2156
pubmed: 28449776
N Engl J Med. 2017 May 11;376(19):1879-1881
pubmed: 28317425
Eur J Prev Cardiol. 2019 May;26(8):824-835
pubmed: 30739508
Lancet. 2015 Jun 13;385(9985):2383-91
pubmed: 25788230
N Engl J Med. 2018 Sep 06;379(10):924-933
pubmed: 30145934
Circulation. 1995 Feb 1;91(3):912-21
pubmed: 7828326
Lancet. 2017 Nov 4;390(10107):2037-2049
pubmed: 28864331
J Am Coll Cardiol. 2017 Jul 18;70(3):318-327
pubmed: 28705312
JAMA Intern Med. 2017 Nov 1;177(11):1623-1631
pubmed: 28973101
Eur Heart J. 2012 Mar;33(6):734-44
pubmed: 21911339
J Am Coll Cardiol. 2017 Aug 1;70(5):558-568
pubmed: 28750699
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Circulation. 2017 Aug 1;136(5):437-439
pubmed: 28760869
Am J Cardiol. 2011 Jan 15;107(2):145-50
pubmed: 21129718
N Engl J Med. 2017 Jul 13;377(2):143-153
pubmed: 28700845
JAMA. 2004 Sep 22;292(12):1433-9
pubmed: 15383513
PLoS Med. 2008 Jan 8;5(1):e12
pubmed: 18184033
JAMA. 2018 Jul 17;320(3):281-297
pubmed: 29998301
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
J Cardiovasc Comput Tomogr. 2012 Jul-Aug;6(4):274-83
pubmed: 22732201
J Am Coll Cardiol. 2017 May 30;69(21):2665-2667
pubmed: 28545641
Clin Cardiol. 2019 Oct;42(10):982-987
pubmed: 31432542
J Am Coll Cardiol. 2014 Feb 4;63(4):380-406
pubmed: 24355759
Eur Heart J Cardiovasc Imaging. 2015 Apr;16(4):441-8
pubmed: 25473041
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Fam Pract. 2006 Apr;23(2):167-74
pubmed: 16461444
Lancet. 2017 Dec 16;390(10113):2643-2654
pubmed: 28943267
J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58
pubmed: 20338496
J Am Coll Cardiol. 2016 Dec 6;68(22):2467-2478
pubmed: 27908353
JAMA. 2016 Nov 15;316(19):2008-2024
pubmed: 27838722
J Am Coll Cardiol. 2017 Feb 14;69(6):712-744
pubmed: 28007322
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
J Am Coll Cardiol. 2014 Sep 30;64(13):1299-306
pubmed: 25257629
BMJ. 2017 Apr 3;357:j1194
pubmed: 28373173
N Engl J Med. 2015 Apr 2;372(14):1291-300
pubmed: 25773919
Circulation. 2017 Jun 13;135(24):2320-2332
pubmed: 28389572

Auteurs

Deborah Cosmi (D)

Department of Cardiology, Gubbio and GualdoTadino Hospital, Perugia, Italy.

Beatrice Mariottoni (B)

Department of Cardiology, Cortona Hospital, Arezzo, Italy.

Franco Cosmi (F)

Department of Cardiology, Cortona Hospital, Arezzo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH